AO Spine Knowledge Forum Spinal Cord Injury (SCI)
AO Spine KF SCI seeks to define new treatment approaches to enhance outcomes for both traumatic and non-traumatic spinal cord injury patients. In collaboration with key partners, they:
- lead an international, multi-center, randomized, controlled trial;
- have undertaken a series of systematic reviews and developed guidelines;
- combined a large prospective registry to address crucial clinical questions related to the assessment and management of traumatic SCI.
Modulation of Inflammatory ResponsesModulation of Inflammatory Responses Using Neural Crest Derived Dental Pulp Stem Cells Following Acute Spinal Cord Injury
Ryan O’Hare Doig
Brian James, Christopher Freeman, Stan Gronthos
Aims to develop a better understanding of the pathophysiological pathways and effects of stem cell distribution, survival and differentiation, following spinal cord injury using advanced imaging and labelling techniques
AO Spine Research Objectives and Common Data Elements for Degenerative Cervical Myelopathy (RECODE-DCM)
1. Aims to establish a standardized definition for DCM.
2. Create a list of unanswered DCM research questions, ranked according to priority.
3. Create a standardized set of baseline characteristics and outcomes which should be measured in DCM research.
Study website www.aospine.org/recode
Spinal Cord Injury (SCI) Database Merge
Combining data from two existing registries (NACTN and STASCIS)
Principal investigator (PI):
To combine two existing databases on patients with spinal cord injuries treated surgically (NACTN and STASCIS) and to assess descriptive data on injury/surgery details, as well as the ASIA score and complications reported
A multi-center, randomized, placebo-controlled, double-blinded trial of the efficacy and safety of Riluzole in acute spinal cord injury
Principal investigator (PI):
Aims to evaluate the efficacy and safety of Riluzole in the treatment of patients with acute spinal cord injury. The primary objective is to evaluate the superiority of Riluzole, as compared to a placebo, in improving motor outcomes as measured by the ASIA Motor Score at six months follow-up, in patients with acute traumatic spinal cord injury, presenting to hospital less than 12 hours after injury.
Co-sponsored by AO Spine North America, US Department of Defense, Christopher and Dana Reeve Foundation, Ontario Neurotrauma Foundation, Rick Hansen Institute
ClinicalTrials.gov Identifier: NCT01597518
Development of evidence-based clinical guidelines for the treatment of acute spinal cord injury (SCI)
A set of systematic reviews will deliver an understanding of the current state of the field. Based on this knowledge, a global team of clinical experts in SCI will then go through the rigorous process of developing evidence-based clinical guidelines for the treatment of acute spinal cord injury. Injury specific to the five selected topics:
- Use of methylprednisolone
- Timing of decompression
- Role and timing of magnetic resonance imaging
- Type and timing of anticoagulation
- Type and timing of rehabilitation
Co-sponsored by AO Spine North America
Guidelines Special Issue
Access the guidelines here
KF SCI Associate Members
Benjamin Davies, University of Cambridge, Cambridge, UK
Paul Koljonen, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong
Ryan O’Hare Doig, South Australian Health and Medical Research Institute, Adelaide, SA, Australia
Ricardo Rodrigues-Pinto, University of Porto, Porto, Portugal
Jeff Wilson, St. Michael's Hospital, Toronto, ON, Canada